Enovis Continues Organic Growth Ramp

Enovis reported 3Q22 orthopedic sales of $143.7 million, +19.6% compared to the third quarter of 2021. The company's Recon business achieved 15% organic growth, with double-digit growth across all product categories.

Foot and ankle sales enjoyed a rebound after moderate disruption from the STAR ankle product due to channel consolidation...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us